VolitionRX Reports Record Revenue Growth and Expands Nu.Q® Platform in Q1 2025
VolitionRx Ltd. reported a 441% increase in revenue for Q1 2025, driven by commercialization efforts for its Nu.Q platform, with analysts projecting continued growth and a potential revenue of $7.5 million for the fiscal year.
2 minutes to read